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Only case reports or small case series reporting the outcomes of patients with previous mitral valve (MV) surgery undergoing transcatheter aortic valve replacement (TAVR) are available. 1 We performed a systematic review to evaluate the feasibility, procedural risks, and outcomes of TAVR in patients with previous MV surgery.
METHODS
A systematic review of reports of TAVR in patients with previous MV surgery was registered on the PROSPERO database (CRD42017070707) and conducted according to PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines. We searched the PubMed/ MEDLINE and EMBASE databases for relevant articles from inception to August 1, 2017 . In addition, references from key manuscripts were searched manually in a backward snowballing fashion for additional articles. Please refer to Appendix E1 for details regarding the methodology of this study.
RESULTS
We identified 37 reports of 137 patients (24 case reports and 13 case series, range 2-40 patients; see Appendix E1 for supplemental references). Mean age was 75.0 AE 9.6 years, and 101 patients (74%) were female. A median Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM) of 9.9% (interquartile range: 8.9%-16.6%) was reported. MV surgery occurred 13. 4 Approaches were 90 (66%) transfemoral, 37 (27%) transapical, 6 (4%) transaortic, 3 (2%) trans-subclavian, and 1 (<1%) transcarotid. Both balloon-expandable and selfexpanding TAVR valves were used for a variety of MV prostheses ( Figure 1 ). Complications directly related to the interaction of the TAVR and MV prostheses were reported acutely in 3 (2%) patients and delayed in 1 (<1%) ( Table 1) . [2] [3] [4] [5] Of 65 patients without a previous pacemaker, 13 (20%) required pacemakers postprocedurally. Paravalvular leak (PVL) was evaluated in all reports and identified in 54 (40%) patients: grade 1 in 45 (34%); and grade 2 in 9 (7%). Two (1.5%) patients died before discharge. No significant differences in outcomes, including in-hospital mortality, new pacemaker, and PVL, were identified among TAVR valves, procedural approach, or MV prostheses.
DISCUSSION
Our systematic review identified 137 reported cases of TAVR after MV surgery. This procedure appears to be feasible and safe for balloon-expandable and selfexpanding TAVR valves with a variety of MV prostheses. However, rare instances of TAVR valve underexpansion and intraventricular prosthesis-prosthesis clash have been reported. These cases were associated with severe complications, including death and conversion to SAVR. [3] [4] [5] In the majority of reported cases, however, no complications related to direct conflict between the TAVR and MV prostheses were documented, and TAVR in patients with previous MV repair was uniformly successful. Given the extreme-to high-risk nature of these patients (median STS-PROM, 9.9%), the in-hospital mortality of 1.5% appeared excellent.
Current ''real-world'' data from the Transcatheter Valve Therapy (TVT) Registry demonstrates that 11.8% of TAVR patients require a pacemaker within 30 days. 6 Therefore, the 20% rate of new pacemaker implantation in our study may be increased as compared with all patients. The TVT registry does not document echocardiographic data, so the ''real-world'' rate of PVL after TAVR is difficult to ascertain. In recent prospective trials, moderate or worse PVL has been documented before discharge in 2% to 3% of patients. 7 Given our review encompasses all TAVR valves, we cannot determine whether the increased rate of moderate or worse PVL (9%) was primarily due to the presence of MV prostheses or simply a reflection of PVL rates associated with older TAVR valves.
This report is subject to several limitations. We may have missed eligible reports, although we attempted to maximize our search's sensitivity. Although the majority of reported cases document acceptable results, the true incidence of adverse outcomes may be greater, given understandable hesitation to publish poor outcomes and enthusiasm to report positive results. Finally, our review includes many cases in the early era of TAVR. However, no signal was present to suggest that modern TAVR prostheses or the TF approach were associated with different outcomes than earlier generation valves and/or alternative approaches.
In summary, this systematic review of TAVR in patients with previous MV surgery suggests the procedure can be performed safely and successfully. This procedure is associated with increased technical challenges and only should be performed by experienced TAVR implanters. A prospective study or registry is necessary to confirm these findings. 
APPENDIX E1
A systematic review of reports of transcatheter aortic valve replacement (TAVR) in patients with previous mitral valve (MV) surgery was conducted according to PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines 1 and registered in the PROS-PERO database (CRD42017070707) ( Table E1 ). We performed a search of the PubMed/MEDLINE and EMBASE databases for relevant articles from inception to August 1, 2017. All articles with the terms {''transcatheter aortic valve implantation,'' ''TAVI,'' ''transcatheter aortic valve replacement,'' OR ''TAVR''} AND {''mitral valve,'' ''mitral prosthesis,'' ''mitral replacement,'' OR ''mitral repair''} located in the title, abstract, or key words were identified to maximize the sensitivity of the search. Additionally, references from key manuscripts were manually searched in a backward snowballing fashion for additional articles.
Included articles had to meet the following criteria: (1) reporting outcomes of TAVR, (2) in human subjects who had previously undergone mitral valve surgery, and (3) written in English. Any peer-reviewed article meeting these criteria, from case reports to randomized control trials, were eligible for inclusion. Exclusion criteria included articles written in a language other than English, reports of concomitant mitral valve surgery and TAVR (ie, a single surgery addressing both valves), or reports regarding a procedure other than TAVR. The resulting list of citations, minus duplicates, was screened at the title/abstract level by a single author (J.J.S.) to identify potentially pertinent studies. At this stage, articles that lacked original data or focused on topics not covered in this review were removed. The full texts of all remaining manuscripts were retrieved for independent assessment by 2 authors (J.J.S., J.M.D.) ( Figure E1 ). Agreement regarding inclusion after full text assessment was 100% between the independent authors.
Patient-specific data including demographics, MV prosthesis type, interval between MV surgery and TAVR, preoperative risk scores, preoperative imaging results, TAVR characteristics (including valve type, size, and delivery route), TAVR complications (including pacemaker placement, TAVR dysfunction, and MV dysfunction), and inhospital mortality was collected from published reports and tabulated using Excel (Microsoft Corp, Redmond, Wash). Continuous data are reported as mean AE standard deviation in variables with normal distribution and median AE interquartile range in non-normally distributed variables. Categorical data are reported as count (percentage). The primary outcomes of interest were in-hospital mortality and TAVR complications. Subgroup analyses stratified by TAVR valve type (self-expanding vs balloonexpanding) and MV prosthesis type (mechanical vs bioprosthesis vs ring) were performed.
On the basis of the preliminary literature review, the authors expected that the risk of bias of included studies was likely to be high, given that the eligible reports included primarily case reports and small case series with the intent to highlight exceptionally good results or specifically to publish bad results as a warning to others. Confidence in the strength of the body of evidence generated by this systematic review was assessed with GRADE criteria, 2 and given the limited level of evidence available in eligible reports, we assigned a grade of ''low quality'' (ie, further research is likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate) to this report. Nevertheless, we planned to proceed with the investigation given the limited data currently available regarding TAVR in patients with previous MV surgery for 2 main reasons: first, to summarize what is currently known about this procedure; and second, to motivate larger prospective study and/or a registry specific to this procedure. 
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